NCT05519540View on ClinicalTrials.gov

PK Study of Xevinapant (Debio 1143) in Healthy East Asian Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

September 26, 2022

Primary Completion Date

April 21, 2023

Study Completion Date

April 21, 2023

Conditions
Healthy
Interventions
DRUG

Xevinapant (Debio 1143)

All participants (Japanese and non-Japanese) received a single oral dose of 200mg xevinapant (Debio 1143) on Day 1 under fasted condition.

Trial Locations (1)

Unknown

Labcorp Clinical Research Unit Limited, Leeds

All Listed Sponsors
collaborator

Merck KGaA, Darmstadt, Germany

INDUSTRY

lead

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

INDUSTRY